{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:26:21Z","timestamp":1771467981765,"version":"3.50.1"},"reference-count":62,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Portuguese Foundation for Science and Technology","doi-asserted-by":"publisher","award":["UIDB\/00051\/2020"],"award-info":[{"award-number":["UIDB\/00051\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Portuguese Foundation for Science and Technology","doi-asserted-by":"publisher","award":["UIDP\/00051\/2020"],"award-info":[{"award-number":["UIDP\/00051\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Portuguese Foundation for Science and Technology","doi-asserted-by":"publisher","award":["2022.08921.PTDC"],"award-info":[{"award-number":["2022.08921.PTDC"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Portuguese Foundation for Science and Technology","doi-asserted-by":"publisher","award":["PTDC\/MED-FSL\/31719\/2017"],"award-info":[{"award-number":["PTDC\/MED-FSL\/31719\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Portuguese Foundation for Science and Technology","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-031719"],"award-info":[{"award-number":["POCI-01-0145-FEDER-031719"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Portuguese Foundation for Science and Technology","doi-asserted-by":"publisher","award":["847635"],"award-info":[{"award-number":["847635"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"RELAX-2-PAH","award":["UIDB\/00051\/2020"],"award-info":[{"award-number":["UIDB\/00051\/2020"]}]},{"name":"RELAX-2-PAH","award":["UIDP\/00051\/2020"],"award-info":[{"award-number":["UIDP\/00051\/2020"]}]},{"name":"RELAX-2-PAH","award":["2022.08921.PTDC"],"award-info":[{"award-number":["2022.08921.PTDC"]}]},{"name":"RELAX-2-PAH","award":["PTDC\/MED-FSL\/31719\/2017"],"award-info":[{"award-number":["PTDC\/MED-FSL\/31719\/2017"]}]},{"name":"RELAX-2-PAH","award":["POCI-01-0145-FEDER-031719"],"award-info":[{"award-number":["POCI-01-0145-FEDER-031719"]}]},{"name":"RELAX-2-PAH","award":["847635"],"award-info":[{"award-number":["847635"]}]},{"name":"IMPAcT","award":["UIDB\/00051\/2020"],"award-info":[{"award-number":["UIDB\/00051\/2020"]}]},{"name":"IMPAcT","award":["UIDP\/00051\/2020"],"award-info":[{"award-number":["UIDP\/00051\/2020"]}]},{"name":"IMPAcT","award":["2022.08921.PTDC"],"award-info":[{"award-number":["2022.08921.PTDC"]}]},{"name":"IMPAcT","award":["PTDC\/MED-FSL\/31719\/2017"],"award-info":[{"award-number":["PTDC\/MED-FSL\/31719\/2017"]}]},{"name":"IMPAcT","award":["POCI-01-0145-FEDER-031719"],"award-info":[{"award-number":["POCI-01-0145-FEDER-031719"]}]},{"name":"IMPAcT","award":["847635"],"award-info":[{"award-number":["847635"]}]},{"name":"European Union\u2019s Horizon 2020 research and innovation programme","award":["UIDB\/00051\/2020"],"award-info":[{"award-number":["UIDB\/00051\/2020"]}]},{"name":"European Union\u2019s Horizon 2020 research and innovation programme","award":["UIDP\/00051\/2020"],"award-info":[{"award-number":["UIDP\/00051\/2020"]}]},{"name":"European Union\u2019s Horizon 2020 research and innovation programme","award":["2022.08921.PTDC"],"award-info":[{"award-number":["2022.08921.PTDC"]}]},{"name":"European Union\u2019s Horizon 2020 research and innovation programme","award":["PTDC\/MED-FSL\/31719\/2017"],"award-info":[{"award-number":["PTDC\/MED-FSL\/31719\/2017"]}]},{"name":"European Union\u2019s Horizon 2020 research and innovation programme","award":["POCI-01-0145-FEDER-031719"],"award-info":[{"award-number":["POCI-01-0145-FEDER-031719"]}]},{"name":"European Union\u2019s Horizon 2020 research and innovation programme","award":["847635"],"award-info":[{"award-number":["847635"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pulmonary hypertension (PH) is a progressive condition that affects the pulmonary vessels, but its main prognostic factor is the right ventricle (RV) function. Many mice\/rat models are used for research in PAH, but results fail to translate to clinical trials. This study reviews studies that test interventions on pulmonary artery banding (PAB), a model of isolated RV disfunction, and PH models. Multiple tested drugs both improved pulmonary vascular hemodynamics in PH models and improved RV structure and function in PAB animals. PH models and PAB animals frequently exhibited similar results (73.1% concordance). Macitentan, sildenafil, and tadalafil improved most tested pathophysiological parameters in PH models, but almost none in PAB animals. Results are frequently not consistent with other studies, possibly due to the methodology, which greatly varied. Some research groups start treating the animals immediately, and others wait up to 4 weeks from model induction. Treatment duration and choice of anaesthetic are other important differences. This review shows that many drugs currently under research for PAH have a cardioprotective effect on animals that may translate to humans. However, a uniformization of methods may increase comparability between studies and, thus, improve translation to clinical trials.<\/jats:p>","DOI":"10.3390\/ijms242115539","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T11:34:47Z","timestamp":1698147287000},"page":"15539","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic Approaches in Pulmonary Arterial Hypertension with Beneficial Effects on Right Ventricular Function\u2014Preclinical Studies"],"prefix":"10.3390","volume":"24","author":[{"given":"Andr\u00e9","family":"Balsa","sequence":"first","affiliation":[{"name":"Cardiovascular R&D Centre\u2014UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2203-436X","authenticated-orcid":false,"given":"Rui","family":"Ad\u00e3o","sequence":"additional","affiliation":[{"name":"Cardiovascular R&D Centre\u2014UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal"},{"name":"Department of Pharmacology and Toxicology, School of Medicine, Complutense University of Madrid, 28040 Madrid, Spain"},{"name":"CIBER of Respiratory Diseases (CIBERES), 28029 Madrid, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1527-3776","authenticated-orcid":false,"given":"Carmen","family":"Br\u00e1s-Silva","sequence":"additional","affiliation":[{"name":"Cardiovascular R&D Centre\u2014UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal"},{"name":"Faculty of Nutrition and Food Sciences, University of Porto, 4150-180 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1801887","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and Pathobiology of Pulmonary Hypertension: State of the Art and Research Perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1183\/09059180.00006711","article-title":"Prognostic factors in pulmonary arterial hypertension: Assessing the course of the disease","volume":"20","author":"Howard","year":"2011","journal-title":"Eur. Respir. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ruaro, B., Salton, F., Baratella, E., Confalonieri, P., Geri, P., Pozzan, R., Torregiani, C., Bulla, R., Confalonieri, M., and Matucci-Cerinic, M. (2022). An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients. Diagnostics, 12.","DOI":"10.3390\/diagnostics12030616"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.phrs.2017.08.003","article-title":"Animal models of pulmonary arterial hypertension: A systematic review and meta-analysis of data from 6126 animals","volume":"125","author":"Sztuka","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/ame2.12220","article-title":"Experimental animal models of pulmonary hypertension: Development and challenges","volume":"5","author":"Wu","year":"2022","journal-title":"Anim. Models Exp. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bph.15444","article-title":"Animal models of pulmonary hypertension: Getting to the heart of the problem","volume":"179","author":"Dignam","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Yang, Y., Lin, F., Xiao, Z., Sun, B., Wei, Z., Liu, B., Xue, L., and Xiong, C. (2020). Investigational pharmacotherapy and immunotherapy of pulmonary arterial hypertension: An update. Biomed. Pharmacother., 129.","DOI":"10.1016\/j.biopha.2020.110355"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.vph.2018.08.004","article-title":"Systematic review and meta-analysis of interventions tested in animal models of pulmonary hypertension","volume":"110","author":"Sztuka","year":"2018","journal-title":"Vasc. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Novoyatleva, T. (2023). Pulmonary Hypertension: New Insights and Recent Advances from Basic Science to Translational Approaches. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24108462"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jacbts.2020.07.011","article-title":"Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension","volume":"5","author":"Prisco","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/bph.15016","article-title":"Current and future treatments of pulmonary arterial hypertension","volume":"178","author":"Sommer","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/cvr\/cvy076","article-title":"Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension","volume":"114","author":"Adao","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijcard.2019.06.065","article-title":"Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure","volume":"293","author":"Andersen","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1164\/rccm.201703-0502OC","article-title":"ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension","volume":"197","author":"Budas","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1253\/circj.CJ-09-0580","article-title":"Sodium Valproate, a Histone Deacetylase Inhibitor, but Not Captopril, Prevents Right Ventricular Hypertrophy in Rats","volume":"74","author":"Cho","year":"2010","journal-title":"Circ. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1165\/rcmb.2019-0317OC","article-title":"Heart Rate Reduction Improves Right Ventricular Function and Fibrosis in Pulmonary Hypertension","volume":"63","author":"Ishii","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.ijcard.2012.06.129","article-title":"Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling","volume":"167","author":"Kojonazarov","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10456-021-09812-7","article-title":"Inhibition of the prolyl isomerase Pin1 improves endothelial function and attenuates vascular remodelling in pulmonary hypertension by inhibiting TGF-beta signalling","volume":"25","author":"Kurakula","year":"2022","journal-title":"Angiogenesis"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/ATVBAHA.120.315731","article-title":"Identification of Celastrol as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension and Right Ventricular Failure Through Suppression of Bsg (Basigin)\/CyPA (Cyclophilin A)","volume":"41","author":"Kurosawa","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"756226","DOI":"10.3389\/fphar.2021.756226","article-title":"Dapagliflozin Has No Protective Effect on Experimental Pulmonary Arterial Hypertension and Pulmonary Trunk Banding Rat Models","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2045894020947283","DOI":"10.1177\/2045894020947283","article-title":"Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats","volume":"10","author":"Mamazhakypov","year":"2020","journal-title":"Pulm. Circ."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/cvr\/cvv244","article-title":"Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension","volume":"109","author":"Adao","year":"2016","journal-title":"Cardiovasc. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1161\/CIRCULATIONAHA.120.047626","article-title":"Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension","volume":"142","author":"Omura","year":"2020","journal-title":"Circulation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1701024","DOI":"10.1183\/13993003.01024-2017","article-title":"Impact of the mitochondria-targeted antioxidant MitoQ on hypoxia-induced pulmonary hypertension","volume":"51","author":"Pak","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00109-009-0524-6","article-title":"The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: Resuscitating the hibernating right ventricle","volume":"88","author":"Piao","year":"2010","journal-title":"J. Mol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1161\/CIRCULATIONAHA.112.109868","article-title":"GRK2-Mediated Inhibition of Adrenergic and Dopaminergic Signaling in Right Ventricular Hypertrophy Therapeutic Implications in Pulmonary Hypertension","volume":"126","author":"Piao","year":"2012","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/cvr\/cvp002","article-title":"Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling","volume":"82","author":"Schafer","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1165\/rcmb.2020-0105OC","article-title":"Increased MAO-A Activity Promotes Progression of Pulmonary Arterial Hypertension","volume":"64","author":"Sun","year":"2021","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.hrthm.2022.02.003","article-title":"Stabilization of RyR2 maintains right ventricular function, reduces the development of ventricular arrhythmias, and improves prognosis in pulmonary hypertension","volume":"19","author":"Tanaka","year":"2022","journal-title":"Heart Rhythm"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1164\/rccm.201812-2275OC","article-title":"Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension","volume":"200","author":"Kurakula","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1055\/s-0033-1355444","article-title":"Experimental models of right heart failure: A window for translational research in pulmonary hypertension","volume":"34","author":"Guihaire","year":"2013","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Mamazhakypov, A., Sommer, N., Assmus, B., Tello, K., Schermuly, R.T., Kosanovic, D., Sarybaev, A.S., Weissmann, N., and Pak, O. (2021). Novel Therapeutic Targets for the Treatment of Right Ventricular Remodeling: Insights from the Pulmonary Artery Banding Model. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18168297"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.4250\/jcvi.2019.0104","article-title":"Echocardiographic Screening Methods for Pulmonary Hypertension: A Practical Review","volume":"28","author":"Jang","year":"2020","journal-title":"J. Cardiovasc. Imaging"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.matbio.2018.01.010","article-title":"Right ventricular fibrosis and dysfunction: Actual concepts and common misconceptions","volume":"68\u201369","author":"Egemnazarov","year":"2018","journal-title":"Matrix Biol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Rai, N., Veeroju, S., Schymura, Y., Janssen, W., Wietelmann, A., Kojonazarov, B., Weissmann, N., Stasch, J.P., Ghofrani, H.A., and Seeger, W. (2018). Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding. Biomed. Res. Int., 2018.","DOI":"10.1155\/2018\/3293584"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/eurjhf\/hfs094","article-title":"Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle","volume":"14","author":"Borgdorff","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"H361","DOI":"10.1152\/ajpheart.00843.2013","article-title":"Sildenafil treatment in established right ventricular dysfunction improves diastolic function and attenuates interstitial fibrosis independent from afterload","volume":"307","author":"Borgdorff","year":"2014","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1164\/rccm.200302-282OC","article-title":"Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats","volume":"169","author":"Schermuly","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1510\/icvts.2006.147033","article-title":"Oral sildenafil prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats","volume":"6","author":"Liu","year":"2007","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1538\/expanim.15-0070","article-title":"Preventive effect of sildenafil on right ventricular function in rats with monocrotaline-induced pulmonary arterial hypertension","volume":"65","author":"Yoshiyuki","year":"2016","journal-title":"Exp. Anim."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s10741-022-10239-5","article-title":"Therapeutic augmentation of NO-sGC-cGMP signalling: Lessons learned from pulmonary arterial hypertension and heart failure","volume":"27","author":"Triposkiadis","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1136\/heartjnl-2017-312865","article-title":"Phosphodiesterase-5 inhibitors and the heart: Compound cardioprotection?","volume":"104","author":"Hutchings","year":"2018","journal-title":"Heart"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Vanderpool, R.R., Gorelova, A., Ma, Y., Alhamaydeh, M., Baust, J., Shiva, S., Tofovic, S.P., Hu, J., Nouraie, S.M., and Gladwin, M.T. (2022). Reversal of Right Ventricular Hypertrophy and Dysfunction by Prostacyclin in a Rat Model of Severe Pulmonary Arterial Hypertension. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105426"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Tang, Y., Tan, S., Li, M., Tang, Y., Xu, X., Zhang, Q., Fu, Q., Tang, M., He, J., and Zhang, Y. (2022). Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension. BMC Pulm. Med., 22.","DOI":"10.1186\/s12890-022-01939-7"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12933-022-01614-5","article-title":"Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling","volume":"21","author":"Wu","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/cvr\/cvaa200","article-title":"Additive protective effects of sacubitril\/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension","volume":"117","author":"Chaumais","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e005819","DOI":"10.1161\/CIRCHEARTFAILURE.119.005819","article-title":"Treatment of Pulmonary Hypertension with Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril\/Valsartan","volume":"12","author":"Clements","year":"2019","journal-title":"Circ. Heart Fail."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e015708","DOI":"10.1161\/JAHA.119.015708","article-title":"Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension","volume":"9","author":"Benza","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/CIRCULATIONAHA.112.103176","article-title":"Histone deacetylation inhibition in pulmonary hypertension: Therapeutic potential of valproic acid and suberoylanilide hydroxamic acid","volume":"126","author":"Zhao","year":"2012","journal-title":"Circulation"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Lan, B., Hayama, E., Kawaguchi, N., Furutani, Y., and Nakanishi, T. (2015). Therapeutic efficacy of valproic acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertension. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0117211"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1164\/rccm.201007-1106OC","article-title":"Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats","volume":"183","author":"Bogaard","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_53","first-page":"e58050","article-title":"A Pulmonary Trunk Banding Model of Pressure Overload Induced Right Ventricular Hypertrophy and Failure","volume":"141","author":"Andersen","year":"2018","journal-title":"J. Vis. Exp."},{"key":"ref_54","first-page":"CD012621","article-title":"Phosphodiesterase 5 inhibitors for pulmonary hypertension","volume":"1","author":"Barnes","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jcmg.2021.07.027","article-title":"The REPAIR Study: Effects of Macitentan on RV Structure and Function in Pulmonary Arterial Hypertension","volume":"15","author":"Channick","year":"2022","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension","volume":"373","author":"Galie","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"eaao4583","DOI":"10.1126\/scitranslmed.aao4583","article-title":"Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients","volume":"9","author":"Michelakis","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e024449","DOI":"10.1161\/JAHA.121.024449","article-title":"Effect of Sacubitril\/Valsartan on the Right Ventricular Function and Pulmonary Hypertension in Patients with Heart Failure with Reduced Ejection Fraction: A Systematic Review and Meta-Analysis of Observational Studies","volume":"11","author":"Zhang","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/ehf2.13952","article-title":"Sacubitril\/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension","volume":"9","author":"Codina","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cardfail.2014.02.005","article-title":"Functional improvement in pulmonary arterial hypertension patients treated with ivabradine","volume":"20","author":"Correale","year":"2014","journal-title":"J. Card. Fail."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pupt.2017.03.009","article-title":"Sorafenib as a potential strategy for refractory pulmonary arterial hypertension","volume":"44","author":"Kimura","year":"2017","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/clpt.2009.217","article-title":"A dosing\/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension","volume":"87","author":"Maitland","year":"2010","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/21\/15539\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:11:05Z","timestamp":1760130665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/21\/15539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":62,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["ijms242115539"],"URL":"https:\/\/doi.org\/10.3390\/ijms242115539","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]}}}